Penumbra (PEN) Net Equity Issued and Repurchased (2017)

Penumbra's (PEN) quarterly Net Equity Issued and Repurchased came in at $2000.0 in Q4 2017, up 100.67% on a QoQ basis from -$298000.0 in Q2 2017.

Penumbra (PEN) Net Equity Issued and Repurchased (2017) Analysis & Trends

Penumbra (PEN) has 1 years of Net Equity Issued and Repurchased data on file, last reported at $2000.0 in Q4 2017.

On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $2000.0 in Q4 2017; TTM through Sep 2018 was $2000.0, a 100.0% decrease from a year earlier, with the FY2020 full-year figure at $134.8 million, changed N/A from the prior year.
Net Equity Issued and Repurchased for Q4 2017 stood at $2000.0, up from -$298000.0 in the prior quarter.
Over the last five years, Net Equity Issued and Repurchased for PEN reached as high as $106.6 million in Q1 2017 and fell as low as -$298000.0 in Q2 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	-
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	-
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	97.00 Mn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	-
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	-
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	12.70 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	-
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	-
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	-
10	Penumbra	12.48 Bn	11.87 Bn	253.41 Mn	-

Download Data